Amgen Quarterly Cash Flow Statement
NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amgen free cash flow
In the quarter ended Jun 30, 2026, Amgen generated $4.00 billion of operating cash flow and spent $513.0 million on capital expenditures. That left free cash flow of $3.49 billion, a free-cash-flow margin of 34.7% of revenue. Free cash flow was up 82.6% from the prior year's $1.91 billion.
Amgen returned $1.36 billion to shareholders through dividends, equal to 39% of free cash flow. Free cash flow covered dividend payments 2.6 times.
Summary generated from market data by MetaCap's automated system. Methodology
Amgen cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 2.38B | 1.82B | 1.33B | 3.22B | 1.43B | 1.73B | 627.00M | 2.83B | 746.00M | -113.00M | 767.00M | 1.73B |
| Net Income growth (YoY) | +65.85% | +5.14% | +112.60% | +13.64% | +91.96% | — | -18.25% | +63.58% | -45.90% | -103.98% | -52.54% | -19.27% |
| Depreciation & Amortization | 1.11B | 1.12B | 1.13B | 1.31B | 1.34B | 1.39B | 1.40B | 1.40B | 1.40B | 1.40B | 1.38B | 895.00M |
| Stock-Based Compensation | 165.00M | 75.00M | 125.00M | 127.00M | 157.00M | 85.00M | 134.00M | 136.00M | 157.00M | 103.00M | 161.00M | 104.00M |
| Change in Working Capital | -1.56B | 935.00M | -2.09B | -5.00M | 115.00M | -802.00M | 571.00M | -121.00M | 962.00M | 1.17B | -351.00M | -531.00M |
| Operating Cash Flow | 4.00B | 2.19B | 1.60B | 4.68B | 2.28B | 1.39B | 4.77B | 3.57B | 2.46B | 689.00M | 538.00M | 2.76B |
| Capital Expenditures | -513.00M | -712.00M | -642.00M | -436.00M | -369.00M | -411.00M | -371.00M | -257.00M | -238.00M | -230.00M | -249.00M | -248.00M |
| Investing Cash Flow | -569.00M | -716.00M | -693.00M | -414.00M | -389.00M | -447.00M | -402.00M | -210.00M | -217.00M | -217.00M | -27.09B | -262.00M |
| Dividends Paid | -1.36B | -1.36B | -1.28B | -1.28B | -1.28B | -1.28B | -1.21B | -1.21B | -1.21B | -1.21B | -1.14B | -1.14B |
| Share Repurchases | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Issued | 0 | 3.96B | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 4.00B | 1.00M |
| Debt Repaid | 0 | -833.00M | 0 | -1.50B | -1.00B | -2.50B | 0 | -2.20B | -1.40B | 0 | 0 | -750.00M |
| Financing Cash Flow | -1.48B | 1.44B | -1.23B | -2.85B | -2.67B | -4.11B | -1.41B | -3.65B | -2.65B | -1.71B | 2.75B | -2.00B |
| Net Change in Cash | 1.95B | 2.91B | -316.00M | 1.42B | -782.00M | -3.16B | 2.96B | -290.00M | -407.00M | -1.24B | -23.80B | 493.00M |
| Free Cash Flow | 3.49B | 1.48B | 961.00M | 4.25B | 1.91B | 980.00M | 4.40B | 3.31B | 2.22B | 459.00M | 289.00M | 2.51B |
This table shows 12 quarterly periods of Amgen's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMGN's reporting calendar. What is a cash flow statement?